N-乙酰半胱氨酸对肺纤维化合并肺气肿综合征患者血清炎症细胞因子的影响

张燕; 李岚岚; 罗懿; 李国庆; 黄勇

doi:10.16016/j.1000-5404.201712289

您当前的位置：

首页 >

文章列表页 >

N-乙酰半胱氨酸对肺纤维化合并肺气肿综合征患者血清炎症细胞因子的影响

临床医学 | 更新时间：2026-01-09

- N-乙酰半胱氨酸对肺纤维化合并肺气肿综合征患者血清炎症细胞因子的影响
- Effects of N-acetylcysteine on serum inflammatory cytokines in patients with combined pulmonary fibrosis and emphysema
- 第三军医大学学报 2018年40卷第15期页码：1394-1398
- 作者机构：
  
  1.400013 重庆, 重庆市人民医院:呼吸内科
  2.400013 重庆, 重庆市人民医院:检验科
- 作者简介：
  
  [ 黄勇, E-mail:yonhuang@163.com HUANG Yong, E-mail:yonhuang@163.com
- 基金信息：
  
  重庆市卫生局医学科研计划项目(2012-2-201);重庆市渝中区科技计划项目(20140125)
- DOI：10.16016/j.1000-5404.201712289
  中图分类号： R392.3;R563.3;R977.4
- 收稿：2017-12-30，
  
  修回：2018-03-17，
  
  纸质出版：2018-08-15
- 稿件说明：
移动端阅览
张燕, 李岚岚, 罗懿, 等. N-乙酰半胱氨酸对肺纤维化合并肺气肿综合征患者血清炎症细胞因子的影响[J]. 第三军医大学学报, 2018,40(15):1394-1398.

Yan ZHANG, Lanlan LI, Yi LUO, et al. Effects of N-acetylcysteine on serum inflammatory cytokines in patients with combined pulmonary fibrosis and emphysema[J]. Journal of Third Military Medical University, 2018, 40(15): 1394-1398.
张燕, 李岚岚, 罗懿, 等. N-乙酰半胱氨酸对肺纤维化合并肺气肿综合征患者血清炎症细胞因子的影响[J]. 第三军医大学学报, 2018,40(15):1394-1398. DOI： 10.16016/j.1000-5404.201712289.

Yan ZHANG, Lanlan LI, Yi LUO, et al. Effects of N-acetylcysteine on serum inflammatory cytokines in patients with combined pulmonary fibrosis and emphysema[J]. Journal of Third Military Medical University, 2018, 40(15): 1394-1398. DOI： 10.16016/j.1000-5404.201712289.

摘要

目的

探讨N-乙酰半胱氨酸（N-acetylcysteine，NAC）对肺纤维化合并肺气肿综合征（combined pulmonary fibrosis and emphysema syndrome，CPFE）患者血清炎症细胞因子的影响。

方法

将2013年6月至2016年6月在重庆市人民医院呼吸内科门诊及住院的CPFE患者112例按照入组先后顺序排序，单号为治疗组，双号为对照组，每组各56例。两组都给予西医常规抗炎、支气管扩张剂及氧疗等基本治疗，治疗组除了给予基本治疗，还给予口服NAC治疗12个月。于治疗前，治疗3、6、9、12个月分别抽取受试者早晨空腹静脉血并处理，留取标本，运用酶联免疫法对各标本中的IL-8、TNF-α、TGF-β1、VEGF水平进行定量检测。

结果

从NAC治疗6个月后，治疗组与对照组比较IL-8、TNF-α、TGF-β1水平明显下降（

0.001），VEGF水平明显升高（

0.001）。且随着治疗时间的推移，后一时间点细胞因子水平的改善比前一时间点更显著。

结论

NAC治疗CPFE综合征时，随着时间的推移可以显著改善IL-8、TNF-α、TGF-β1、VEGF等细胞因子水平的表达。

Abstract

Objective

To explore the effect of N-acetylcysteine (NAC) on serum inflammatory cytokines in the patients with combined pulmonary fibrosis and emphysema syndrome (CPFE).

Methods

From June 2013 to June 2016

112 CPFE outpatient and hospitalized patients admitted in the respiratory department were prospectively recruited in this study

and according to the order of entry

these with odd number were assigned into the treatment group

while those of double number into the control group

with 56 cases in each group. Both groups were given anti-inflammatory agents

bronchodilator and oxygen therapy and other basic therapy

while the patients of the treatment group were given oral NAC treatment for 12 months additionally. Morning fasting venous blood samples were harvested before treatment and in 3

9 and 12 months after treatment

and the levels of IL-8

TNF-α

TGF-β1 and VEGF were detected with enzyme-linked immunoassay.

Results

Compared with the control group

the levels of IL-8

TNF-α and TGF-β1 were decreased significantly (

0.001)

and that of VEGF was increased obviously (

0.001) in 6 months after treatment. Moreover

with the elapse of time

more significant improvement was observed in the cytokine levels than those at the previous time points.

Conclusion

In the treatment of CPFE syndrome

NAC can significantly improve the expression of cytokines

such as IL-8

TNF-α

TGF-β1 and VEGF as time goes on.

关键词

Keywords

references

LIN H, JIANG S. Combined pulmonary fibrosis and emphysema (CPFE):an entity different from emphysema or pulmonary fibrosis alone[J]. J Thorac Dis, 2015, 7(4):767-779. DOI:10.3978/j.issn.2072-1439.2015.04.17.

COTTIN V, NUNES H, BRILLET P Y, et al . Combined pulmonary fibrosis and emphysema:a distinct underrecognised entity[J ] . Eur Respir J, 2005, 26(4):586-593. DOI:10.1183/09031936.05.00021005.

TASAKA S, MIZOGUCHI K, FUNATSU Y, et al . Cytokine profile of bronchoalveolar lavage fluid in patients with combined pulmonary fibrosis and emphysema[J ] . Respirology, 2012, 17(5):814-820. DOI:10.1111/j.1440-1843.2012.02182.x.

EL-MEGHARBEL S M, HAMZA R Z, REFAT M S. Synthesis, chemical identification, antioxidant capacities and immunological evaluation studies of a novel silver(I) carbocysteine complex[J]. Chem Biol Interact, 2014, 220:169-180. DOI:10.1016/j.cbi.2014.06.024.

JANKOWICH M D, SHARON R. Combined pulmonary fibrosis and emphysema alters physiology but has similar mortality to pulmonary fibrosis without emphysema[J]. Lung, 2010(5):365-373. DOI:10.1007/s00408-010-9251-6.

XU L, BIAN W, GU X H, et al . Differing expression of cytokines and tumor markers in combined pulmon ary fibrosis and emphysema compared to emphysema and pulmonary fibrosis[J ] . COPD, 2017, 14(2):245-250. DOI:10.1080/15412555.2017.1278753.

FAGHIHI M, ALIZADEH A M, KHORI V, et al . The role of nitric oxide, reactive oxygen species, and protein kinase C in oxytocin-induced cardioprotection in ischemic rat heart[J ] . Peptides, 2012, 37(2):314-319. DOI:10.1016/j.peptides.2012.08.001.

CICCARESE F, ATTINÁ D, ZOMPATORI M. Combined pulmonary fibrosis and emphysema (CPFE):what radiologist should know[J]. Radiol Med, 2016, 121(7):564-572. DOI:10.1007/s11547-016-0627-4.

中华医学会呼吸病学分会.特发性肺(间质)纤维化诊断和治疗指南(草案)[J].中华结核和呼吸杂志, 2002, 25(7):387-389.

The Chinese Medical Association for Respiratory Diseases. Guidelines for the diagnosis and treatment of idiopathic pulmonary(interstitial)fibrosis (Draft)[J].Chin J Tuberc Respir Dis, 2002, 25(7):387-389.

杨天芸, 宋琳, 蔡蓉, 等.肺纤维化合并肺气肿的临床表现及影像学特点[J].临床肺科杂志, 2015, 20(11):2017-2019, 2020.DOI:10.3969/j.issn.1009-6663.2015.11.025.

YANGT Y, SONG L, CAI R, et al . The clinical and imaging features of combined pulmonary fibrosis and emphysema[J ] . Clin Pulmonary J, 2015, 20(11):2017-2019, 2020.DOI:10.3969/j.issn.1009-6663.2015.11.025.

胡安邦, 李卫青.慢性阻塞性肺疾病合并肺纤维化的中西医研究进展[J].山西中医, 2012, 28(6):57-58, 62.DOI:10.3969/j.issn.1000-7156.2012.06.031.

HUA B, LI W Q. The progress of Chinese and Western Medicine on chronic obstructive pulmonary disease combined with pulmonary fibrosis[J]. Shanxi Chin Med, 2012, 28(6):57-58, 62. DOI:10.3969/j.issn.1000-7156.2012.06.031.

GAO J, ZHAN B. The effects of Ang-1, IL-8 and TGF-β1 on the pathogenesis of COPD[J]. Mol Med Rep, 2012, 6(5):1155-1159. DOI:10.3892/mmr.2012.1059.

ROGLIANI P, MURA M, MATTIA P, et al . HRCT and histopathological evaluation of fibrosis and tissue destruction in IPF associated with pulmonary emphysema[J ] . Respir Med, 2008, 102(12):1753-1761. DOI:10.1016/j.rmed.2008.07.010.

LUNDBLAD L K A, Thompson-Figueroa J, Leclair T, et al . Tumor necrosis factor-α overexpression in lung disease[J ] . Am J Respir Critical Care Med, 2005, 171(12):1363-1370. DOI:10.1164/rccm.200410-1349oc.

WILLIS B C, BOROK Z. TGF-beta-induced EMT:mechanisms and implications for fibrotic lung disease[J]. Am J Physiol Lung Cell Mol Physiol, 2007, 293(3):L525-L534. DOI:10.1152/ajplung.00163.2007.

LI X, LIU L, SHEN Y, et al . MicroRNA-26a modulates transforming growth factor beta-1-induced proliferation in human fetal lung fibroblasts[J ] . Biochem Biophys Res Commun, 2014, 454(4):512-517. DOI:10.1016/j.bbrc.2014.10.106.

郑洪.血管内皮生长因子与呼吸系统疾病[J].临床荟萃, 2008, 23(4):302-304. DOI:10.3969/j.issn.1004-583X.2008.04.044.

ZHENG H.Vascular endothelial growth factor and respiratory system disease[J]. Clin Metatol, 2008, 23(4):302-304.DOI:10.3969/j.issn.1004-583X.2008.04.044.

KRISTAN S S, MARC M M, KERN I, et al . Airway angiogenesis in stable and exacerbated chronic obstructive pulmonary disease[J ] . Scand J Immunol, 2012, 75(1):109-114. DOI:10.1111/j.1365-3083.2011.02623.x.

郭瑛, 李燕芹, 刘斌, 等.血管内皮功能变化与慢性阻塞性肺疾病的关系[J].上海交通大学学报(医学版), 2010, 30(9):1152-1155. DOI:10.3969/j.issn.1674-8115.2010.09.032.

GUO Y, LI Y Q, LIU B, et al . Relationship between vascular endothelial function and chronic obstructive pulmonary disease[J ] . J Shanghai Jiaotong Univ(Med Sci), 2010, 30(9):1152-1155. DOI:10.3969/j.issn.1674-8115.2010.09.032.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

N-乙酰半胱氨酸对肺纤维化合并肺气肿综合征患者氧化应激和肺功能的影响

不同剂量糖皮质激素联合N-乙酰半胱氨酸治疗特发性肺纤维化的研究

氧化应激对肺泡Ⅱ型上皮细胞MAPKs的激活及N-乙酰半胱氨酸的干预作用